全文获取类型
收费全文 | 27231篇 |
免费 | 1743篇 |
国内免费 | 124篇 |
专业分类
耳鼻咽喉 | 229篇 |
儿科学 | 765篇 |
妇产科学 | 609篇 |
基础医学 | 4190篇 |
口腔科学 | 1343篇 |
临床医学 | 2207篇 |
内科学 | 5827篇 |
皮肤病学 | 737篇 |
神经病学 | 2784篇 |
特种医学 | 677篇 |
外科学 | 2732篇 |
综合类 | 85篇 |
一般理论 | 7篇 |
预防医学 | 1832篇 |
眼科学 | 497篇 |
药学 | 2375篇 |
中国医学 | 139篇 |
肿瘤学 | 2063篇 |
出版年
2023年 | 235篇 |
2022年 | 213篇 |
2021年 | 803篇 |
2020年 | 572篇 |
2019年 | 796篇 |
2018年 | 955篇 |
2017年 | 705篇 |
2016年 | 796篇 |
2015年 | 952篇 |
2014年 | 1147篇 |
2013年 | 1454篇 |
2012年 | 2265篇 |
2011年 | 2476篇 |
2010年 | 1293篇 |
2009年 | 1132篇 |
2008年 | 1847篇 |
2007年 | 1806篇 |
2006年 | 1646篇 |
2005年 | 1515篇 |
2004年 | 1377篇 |
2003年 | 1204篇 |
2002年 | 1059篇 |
2001年 | 282篇 |
2000年 | 280篇 |
1999年 | 273篇 |
1998年 | 144篇 |
1997年 | 147篇 |
1996年 | 116篇 |
1995年 | 109篇 |
1994年 | 104篇 |
1993年 | 64篇 |
1992年 | 152篇 |
1991年 | 107篇 |
1990年 | 110篇 |
1989年 | 123篇 |
1988年 | 92篇 |
1987年 | 91篇 |
1986年 | 74篇 |
1985年 | 65篇 |
1984年 | 40篇 |
1983年 | 40篇 |
1982年 | 26篇 |
1981年 | 27篇 |
1979年 | 33篇 |
1978年 | 40篇 |
1977年 | 21篇 |
1974年 | 25篇 |
1973年 | 36篇 |
1972年 | 26篇 |
1970年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
de Souza Evanice Avelino Alves Felipe Rocha Façanha Josana Nunes Torres Michele Gonçalves Romcy 《Sport Sciences for Health》2022,18(2):473-480
Sport Sciences for Health - The practice of physical activity has been recommended during the pandemic period of COVID-19 as a way of preventing the worsening of physical and mental health. After... 相似文献
3.
Zancanella Edilson do Prado Lucila Fernandes de Carvalho Luciane Bizari Machado Júnior Almiro J. Crespo Agrício Nubiato do Prado Gilmar Fernandes 《Sleep & breathing》2022,26(1):117-123
Sleep and Breathing - There are no studies comparing tests performed at home with those carried out in the laboratory, using the same device. The only studies that have been performed... 相似文献
4.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
5.
Marc Evans MD Susanne Engberg MD Mads Faurby MSc João Diogo Da Rocha Fernandes MSc Pollyanna Hudson MSc William Polonsky PhD 《Diabetes, obesity & metabolism》2022,24(3):377-390
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety-two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%-84.3%]) or persistent (median [range] 47.7% [16.9%-94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget-neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes. 相似文献
6.
Iacopo Chiodini Daniela Merlotti Alberto Falchetti 《Expert opinion on pharmacotherapy》2020,21(6):721-732
ABSTRACT
Introduction
Glucocorticoid (GC) induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. It develops in a dose and time dependent manner, due to a rapid and transient increase in bone resorption, followed by the inhibition of bone formation. 相似文献7.
Di Kaijun Lomeli Naomi Bota Daniela A. Das Bhaskar C. 《Journal of neuro-oncology》2019,141(2):267-276
Journal of Neuro-Oncology - Magmas (mitochondria-associated protein involved in granulocyte–macrophage colony-stimulating factor signal transduction) is a nuclear gene that encodes the... 相似文献
8.
9.
10.
Fabian Falkenstein Marco Gessi Daniela Kandels Ho-Keung Ng René Schmidt Monika Warmuth-Metz Brigitte Bison Juergen Krauss Rolf-Dieter Kortmann Beate Timmermann Ulrich-Wilhelm Thomale Michael H. Albert Arnulf Pekrun Eberhard Maaß Astrid K. Gnekow Torsten Pietsch 《International journal of cancer. Journal international du cancer》2020,147(8):2159-2175
Reports on pediatric low-grade diffuse glioma WHO-grade II (DG2) suggest an impaired survival rate, but lack conclusive results for genetically defined DG2-entities. We analyzed the natural history, treatment and prognosis of DG2 and investigated which genetically defined sub-entities proved unfavorable for survival. Within the prospectively registered, population-based German/Swiss SIOP-LGG 2004 cohort 100 patients (age 0.8-17.8 years, 4% neurofibromatosis [NF1]) were diagnosed with a DG2. Following biopsy (41%) or variable extent of resection (59%), 65 patients received no adjuvant treatment. Radiologic progression or severe neurologic symptoms prompted chemotherapy (n = 18) or radiotherapy (n = 17). Multiple lines of salvage treatment were necessary for 19/35 patients. Five years event-free survival dropped to 0.44, while 5 years overall survival was 0.90 (median observation time 8.3 years). Extensive genetic profiling of 65/100 DG2 identified Histone3-K27M-mutation in 4, IDH1-mutation in 11, BRAF-V600-mutation in 12, KIAA1549-BRAF-fusions in 6 patients, while the remaining 32 tumor tissues did not show alterations of these genes. Progression to malignant glioma occurred in 12 cases of all genetically defined subgroups within a range of 0.5 to 10.8 years, except for tumors carrying KIAA1549-BRAF-fusions. Histone3-K27M-mutant tumors proved uniformly fatal within 0.6 to 2.4 years. The current LGG treatment strategy seems appropriate for all DG2-entities, with the exemption of Histone3-K27M-mutant tumors that require a HGG-related treatment strategy. Our data confirm the importance to genetically define pediatric low-grade diffuse gliomas for proper treatment decisions and risk assessment. 相似文献